Yatharth Hospitals: Rapid Rise, Big Expectations

Yatharth Hospital & Trauma Care Services, established in 2008, is rapidly emerging as a key private healthcare player in North India. With a market cap of ₹6,040 crore, the group operates 7 hospitals, including two of NCR’s largest, and focuses heavily on metro locations—87% of its beds are in metropolitan areas, driving high patient volumes and improved occupancy rates. The company’s aggressive growth story has turned heads: revenues surged at a CAGR of 29% from ₹123 crore in FY20 to ₹442 crore in FY25, while EBITDA grew at 33% to reach ₹130 crore. Net profits raced from ₹1 crore in FY20 to ₹88 crore in FY25, marking a robust 155% annualized growth. Shareholders have clearly benefitted from this momentum—Yatharth’s share price skyrocketed 90% in just 6 months, leaping from ₹426 in April 2025 to ₹809 as of October 2025. However, it now trades at a lofty PE of 85x, well above the sector average. The stock’s rerating is also supported by strong DII interest, with Kotak Multicap, Bandhan Smallcap, ICICI Prudential Pharma, and SBI Life holding significant stakes. Mukul Agarwal, a prominent investor, added further credibility by buying a 1.1% stake. Strategically, Yatharth focuses on expanding high-margin super-speciality services and upgrading assets, which could boost ARPOB and profitability. However, the high valuation and rapid growth expectation mean risks of execution slippages or a slowdown can quickly hurt sentiment. For current shareholders, the journey so far has been rewarding. Going forward, sustained execution, asset utilization, and prudent capital allocation will decide if Yatharth can justify its premium and continue creating value.